A Study of Effect of Metformin and Gliclazide with and without Atorvastatin on Intimal Medial Thickness of Common Carotid Artery in Patients of Type 2 Diabetes Mellitus

Aim : To evaluate the effect of metformin and gliclazide with and without atorvastatin on Glycemic control, Diabetic dyslipidemia and Serum C-reactive protein levels and their relationship to intimal medial thickness of common carotid artery. Materials and methods : In a prospective, double-blind, parallel and placebo-controlled study, type 2 diabetes mellitus patients randomized to either tab. Gliclazide 40 mg/day, metformin 500mg/day and atorvastatin 20 mg/day or tab. Gliclazide 40 mg/day, metformin 500mg/day and a matched placebo for a period of 24 weeks. Changes from baseline in fasting blood glucose (FBG), glycosylated haemoglobin (HbA1c), lipid profile, including total cholesterol (TC), LDL-C, high-density lipoprotein cholesterol (HDL-C), triglycerides (TG), C–reactive protein (CRP), intimal medial thickness (IMT) and liver enzymes (SGOT, SGPT) were observed. Results : Patients receiving metformin, gliclazide and atorvastatin had significantly greater percent reduction in TC (12.49%), TG (8.29%), LDL-C (18.58%), IMT (11.02%) and CRP (7.63%) and significant increase in HDL-C (10.11%) as compared to patients receiving metformin, gliclazide and placebo (p 0.05). Change in intimal medial thickness showed significant positive correlation with change in CRP. Conclusion s : The present study has indicated that this combination is more useful and beneficial for diabetic patients in lowering raised blood glucose levels within normal range and to prevent its various complications concurrently.